SQUAWK/NEWS
Account
Theme
Account
Menu
Live News EQUITY FLASH L impact

DiaMedica Therapeutics Q3 loss widens on higher R&D costs

DiaMedica Therapeutics Q3 loss widens on higher R&D costs Overview US biopharma firm's Q3 net loss w

ASMBDMACNKTRRCKT

Related stories